Who is 108Labs?
In 2013, 108Labs set out to feed and heal the world with Cellufacturing® innovations.
Then 108Labs created the science behind Biomilq ... and more.
108Labs co-founder Shayne Guiliano first conceived of mammary cell agriculture the evening he acquired 108Labs’ first lab space from RTP Park Foundation while leading a discussion on slaughterhouse tissue acquisition logistics for prospective meat and leather projects with co-founder Leila Strickland.
To pioneer mammary cell agriculture quickly became 108Labs’ mission.
ABOUT THAT PERSONALIZED MILK THING
Proof of Concept and Commerce
After years of R&D in and out of RTP labs experimenting with bovine cells acquired from Randolph Packing slaughterhouse in Ashboro, NC to improve the 108Labs’ mammary cell bioreactor design, 108Labs,LLC contracted with John Cadwell from FiberCell Labs in October 2019 to combine expertises in 3d cell culture to demonstrate scalable biosynthesis of human milk and secretory antibodies utilizing 108Labs’ patent pending methods for producing cell cultured mammalian milk. Special acknowledgement to FiberCell tech Samantha Dostalik, a true cell whisperer.
With the help of leading human milk researchers, 108Labs analyzed bioreactor harvests demonstrating successful biosynthesis of the major human milk molecules including nutritional and antimicrobial proteins and carbs, anti-inflammatory lipids, probiotic HMO, as well as secretory antibodies evolved to nurture and protect newborns from mucosal infection.
108Labs’ animal-free primary mammary cell bioreactor makes it possible to replicate the biosimilar nutritional and anti-microbial molecules of human milk alongside secretory antibodies reflecting the immune memory of a donor against environmental pathogens. Antibodies evolved in donors and produced in the bioreactor can be applied to mucosal surfaces to help protect immunocompromised patients against shared environmental pathogens.
108Labs’ first SBIR application was submitted to the US National Science Foundation on Dec 12, 2019, seeking grant funding to commercialize 108Labs’ mammary cell bioreactor innovations under a newly created brand called Biomilq for productizing 108Labs’ personalized human milk project, with help from Michele Egger. Though 108Labs is no longer working on personalized milk nutraceuticals with Biomilq, Inc, 108Labs’ personalized mammary cell therapeutics project lived on with a new focus beyond just personalized infant nutrition to secretory antibodies and antibody immune memory replication therapeutics.
108Labs' science behind and beyond Biomilq
Personalized mammary cell therapeutics is now under development and licensed exclusively to NeutraSiga Therapeutics and re-branded Cellsimile™ therapeutics with a focus on antibody immune memory transfer.
Cellsimile™
Cellsimile™ services are focused on providing direct-to-consumer passive immunity transfer services using donor cells to replicate human milk and secretory antibodies evolved in donors to provide antimicrobial protection on mucosal surfaces in immunocompromised patients – including but not limited to mothers and newborns.
ODE TO ANTIBODIES
108Labs cell
cultured human
milk AND
milk antibodies!
108Labs Jan 22, ’20 harvest mass spec
Proof of major milk protein biosynthesis
On January 20, 2020, 108Labs successfully created its first cell cultured biosimilar human milk. Proteomics of the January 20th harvest landed March 16th demonstrating 108Labs’ novel production of whole-human milk proteins including all the major caseins and wheys and including bioactive molecules like BSAL and Lactoferrin. In addition to synthesizing the major nutritional and bioactive molecules of human milk, 108Labs created the world’s first biosimilar whole-human secretory IgA antibodies produced in a fully human, non-gmo, animal-free and pathogen-free bioreactor.
The above antibody “baby” photo was imaged at 0.01ug/mL dilution revealing the beautiful hinging exhibited by 108Labs’ biosimilar secretory IgA dimers that naturally confer immunity by protecting mucosal membranes throughout our lives, trapping pathogens in their grip prior to invasion, yielding rarely to the whims of viruses and bacteria once trained to resist.
108Labs Jan 22 harvest chromatograph
Proof of secretory antibody biosynthesis
108Labs contracts with BIOIVT for milk-related specimen acquisition
In February 2020, 108Labs contracted with BioIVT to acquire milk specimen standards and primary mammary cells for R&D. 108Labs and BioIVT continue to work together to develop mammary cell agriculture.
You may have heard of Biomilq
In December 2020, with 108Labs experimental proof of scalable mammary cell agriculture underway, 108Labs co-founders turned focus to fundraising after self-funding 108Labs’ research with family funds since 2013. Shayne and Leila agreed to create a new brand – with the help of Michele Egger – called Biomilq to publicize 108Labs’ mammary cell agriculture in personalized infant nutrition after 108Labs produced its first analytical evidence of human milk production. In January 2020, 108Labs rented lab space at UNC Chapel Hill’s NCore and worked with the NCore analytical services team to study 108Labs bioreactor harvests to look for major components of human milk including Lactose and Casein.
On February 27th, 2020 The Atlantic featured 108Labs’ co-manager Leila Strickland announcing 108Labs’ scientific data under the Biomilq name, disclosing that 108Labs successfully synthesized at least lactose and casein simultaneously, a monumental achievement in itself for a self-funded, family-run biotech with a literal garage full of lab equipment. 108Labs’ announcement went viral around the world under the Biomilq brand, leading to interest from investors into 108Labs technology.
But the casein-lactose announcement was only the tip of the iceberg of what 108Labs had accomplished.
Simple Wes with Human Casein Antibody
First proof of 108Labs scalable milk production
by 108Labs at UNC Chapel Hill NCore Labs, Jan 2020
acknowledgment to NCore employee Olesia Gololobova, PhD for help with WES.
Lactose Kit Results (verified by UC Davis Slupsky lab via metabolomics)
First proof of 108Labs lactose production
by 108Labs at UNC Chapel Hill NCore Labs, Jan 2020
acknowledgment to NCore employee Olesia Gololobova, PhD for help with plate runs.
What else DID 108LABS CREATE?
108Labs
Human Milk
Component
Analysis
108Labs worked to analyze bioreactor harvests for lipid content of milk produced by 108Labs’ mammary cell bioreactor. By identifying key bioactive lipid mediators of fatty acids (also known as oxylipins), Ameer confirmed that 108Labs biosynthesized major bioactive lipids of human milk including anti-inflammatory lipids like Resolvin E1 and many others at concentrations comparable to mother’s milk.
108Labs worked to analyze the metabolomics of bioreactor harvests proving 108Labs biosynthesized the major nutritional, protective and probiotic carbs and HMO of human milk including lactose and 2′-fucosyl lactose amongst many other complex whole-human sugars.
refocus, Refresh, rebrand
108Labs pivots from Biomilq,
continues personalized medicine development
In April 2020, with the global pandemic bearing down and Biomilq, Inc taking off in its own direction, 108Labs’ development focus pivoted from personalized infant supplements to therapeutic benefits of human milk and secretory antibodies beyond the Biomilq brand.
108Labs’ mother’s milk personalization project has transformed into gender-neutral personalized mammary cell therapeutics with a focus on antibody immune memory replication, working to relaunch personalized mammary cell agriculture as a personalized milk and antibody therapeutic soon.
refocus, Refresh, rebrand
108Labs abandons
Biomilq,
launches Cellsimile™ with NeutraSiga
In April 2020, with the global pandemic bearing down, 108Labs development focus pivoted from just personalized infant supplements under the Biomilq brand to therapeutic benefits of human milk and secretory antibodies beyond the Biomilq brand.
108Labs’ Biomilq-branded mother’s milk personalization project has turned into gender-neutral personalized mammary cell therapeutics with a focus on antibody immune memory replication, relaunching personalized mammary cell agriculture as Cellsimile™ personalized antibody therapeutics in partnership with NeutraSiga Therapeutics.
Cellsimile™ antibody therapeutics personalizes mammary cell agriculture beyond nutritional mother’s milk molecules with a focus on replicating biosimilar secretory and blood circulating antibodies reflecting a donor’s immune memory for therapeutic use in immunocompromised patients such as newborns.
Cellsimile™
NeutraSiga’s Cellsimile™ personalized antibody therapy enables any donor – male or female – to produce milk and replicate their antibody immune memory into secretory and blood circulating antibodies for whole-body antibody therapeutics in chosen immunocompromised patients.
Leila Strickland resigns
On March 27th, 2020, co-founder Leila Strickland resigned as a manager-member of 108Labs, LLC to pursue new ventures with Michele Egger at Biomilq, Inc with a focus on personalized infant nutraceuticals, leaving Shayne Guiliano as sole manager-member of 108Labs, LLC. Though Leila remains a treasured former colleague and financial interest owner of 108Labs, LLC, Leila is no longer involved with 108Labs, LLC or 108Labs’ science.
Shayne continues the important work of 108Labs to feed and heal the world with Cellufacturing® innovations, growing new teams and developing new partnerships to build on the amazing cellular agriculture discoveries Shayne and Leila unraveled together at 108Labs since 2013.
108Labs and Infant nutrition
108Labs
launches
Colostrupedics™
whole-human infant formulations
Colostrupedics™
whole-human infant formula with secretory IgA
108Labs set out with a mission in 2013 to feed and heal, and Colostrupedics™ infant formula realizes this vision of using 108Labs Cellufacturing® innovations to nurture and protect humans through our most vulnerable first moments in life.
In April, 2020, 108Labs’ created Colostrupedics™ infant formulations to commercialize the world’s first whole-human milk formulations produced in pathogen-free and animal-free conditions with nutritional and immunological molecules biosimilar to those found in mother’s milk.
Colostrupedics™ formulations can disrupt the infant formula market by introducing the world’s first whole-human infant formula with broadly neutralizing secretory antibodies.
Infant formula ingredients today are dominated by bovine milk extracts and recombinant proteins grown in bacteria and yeast.
108Labs’ Colostrupedics™ infant formula is the first whole-human infant formula exclusively formulated with whole-human molecules including bioactive and nutritional proteins and carbs, probiotic HMO and anti-inflammatory lipids combined with broadly neutralizing secretory antibodies evolved in mother’s milk to nurture and protect us all in our most vulnerable first moments of life.
Antibody heard round the world
108Labs pivots to saving lives in pandemic with Antibodies
108Labs’ successful biosynthesis of secretory milk antibodies using primary cells opens new possibilities for therapeutics and consumable immune memory transfer services. This burden of 108Labs’ discovery coinciding with the dawn of a global pandemic inspired 108Labs to extend 108Labs’ R&D beyond nutritional milk molecules to focus on the immunological benefit of 108Labs’ discoveries for the treatment of infectious disease.
108Labs’ bioreactor also produces hundreds of well studied bioactive antimicrobial milk molecules such as Lactoferrin and Lysozyme, which can synergistically combine with secretory antibodies for immunological benefit against environmental pathogens.
108Labs’ Colostrupedics™ infant formula is the first whole-human infant formula with broadly neutralizing secretory antibodies and fully bioactive whole-human milk molecules produced in a pathogen-free environment and delivered in sterile packaging to maximize nutritional and immunological benefit.
108Labs’ bioreactor also produces hundreds of well studied bioactive antimicrobial milk molecules such as Lactoferrin and Lysozyme, which can synergistically combine with secretory antibodies for immunological benefit against environmental pathogens.
108Labs’ Colostrupedics™ infant formula is the first whole-human infant formula with broadly neutralizing secretory antibodies and fully bioactive whole-human milk molecules produced in a pathogen-free environment and delivered in sterile packaging to maximize nutritional and immunological benefit, and 108Labs is also partnering with NeutraSiga Therapeutics to develop the world’s first drugs and biologicals derived from mammary cell agriculture into Human Immune Milk™ therapeutics.
Mother’s milk is not pathogen-free. Donor milk requires pasteurization which degrades pathogen neutralizing benefits. Mother’s milk also cannot benefit from antibodies evolved around the world because immune memory is localized to a mother’s environment.
108Labs’ Colostrupedics™ whole-human milk molecules delivered alongside human secretory antibodies are the world’s first supply of GRAS-certifiable and biosimilar whole-human milk molecules for use in nutraceuticals and therapeutics without need of pasteurization.
In April 2020, 108Labs first noticed the work of Rebecca Powell, PhD with her research focus on infectious disease and milk molecules amongst Covid survivors, after studying HIV and other pathogens for years. Fast friends, 108Labs and Rebecca’s lab began collaborating to study cells and antibodies in milk of Covid survivors, with Rebecca demonstrating that Covid-surviving mothers produce strongly neutralizing SIgA, and even pre-pandemic unpasteurized milk still exhibits neutralizing benefit against Covid. Rebecca remains a trusted scientific advisor and collaborator with 108Labs, investigating the potential for 108Labs mammary cell agriculture for use in pandemic therapeutics.
Rebecca is a trusted scientific advisor to NeutraSiga assisting in development of Human Immune Milk™ therapeutics and collaborating on basic study of 108Labs’ bioreactor as a ex vivo lactation model and antibody-secreting LLPC niche for therapeutic use.
108LABs BIOLOGICALS and DRUGS
108Labs
partners with
NeutraSiga Therapeutics,Inc
On May 25th, 2020, 108Labs,LLC co-founder Shayne Guiliano founded NeutraSiga Therapeutics, Inc, with seed funding from SSC Ventures and close mentorship from Miguel Galvez, CEO of NBD Nanotechnologies, Inc to focus on Covid antibody discovery and therapeutic development of whole-human antibodies.
In Feb 2021, NeutraSiga Therapeutics became the exclusive licensee of whole-human molecules derived from 108Labs’ mammary cell bioreactor for use in drugs and biologicals comprising NeutraSiga’s Human Immune Milk™ therapeutics to fight infectious disease. NeutraSiga’s first products in development are Covid Human Immune Milk™ applications.
NeutraSiga’s Covid Human Immune Milk™ therapeutics are formulated with antimicrobial milk molecules alongside broadly neutralizing and pathogen-targeting antibodies to provide the broadest spectrum protection against Covid variants, past and future.
What's next?
108Labs is creating the future of food and medicine!
108Labs, LLC and NeutraSiga Therapeutics, Inc are working closely together operating labs and partnering with scientists across the country to continue the important work turning 108Labs’ incredible discoveries into food and medicine to nurture and protect us in our most vulnerable moments.
NeutraSiga’s Cellsimile™ personalized antibody therapeutics may provide prophylactic passive immunity protection for infants by application to mucosal surfaces of biosimilar secretory antibodies reflecting a mother’s naturally-evolved immune memory against environmental pathogens.
108Labs Colostrupedics™ nutraceuticals and NeutraSiga’s Human Immune Milk™ therapeutics are poised to disrupt many fields including infant formula, elder care, infectious disease prevention and treatment, cancer patient prophylactics, or any population that could benefit from the ideal nutrition and passive immunity that 108Labs and NeutraSiga formulations can provide for at risk or immunocompromised persons such as newborns, elders, bone marrow transplantees, first responders and medical professionals.
If you’d like to join 108Labs on our mission to feed and cure with Cellufacturing®, apply here!
Corporate and Press Contact
108Labs,LLC
available from 9-5pm EST
Address 141 W King St., Hillsborough, NC 27278
Email info@108labs.net
v. 919-450-7226
108Labs,LLC – All Rights Reserved © 2021 – info@108labs.net – Cellufacturing® since 2013